All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Ongoing | 2004-003075-37 | CHOEP-14 + rituximab with CNS prophylaxis in patients less than 65 years with Diffuse Large B-Cell Lymphoma/Follicular Lymphoma grade III, stage II-IV with risk factors (age adjusted IPI) ≥ 2. A phase... | not-yet-due | |
Ongoing | 2006-000389-35 | A Nordic phase II study of peripheral T-cell lymphomas based on dose-intensive induction and high-dose consolidation with autologous stem cell rescue | not-yet-due | |
Reported results | 2006-004772-12 | Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by ma... | 2022-07-13 | due-trials |
Listed as ongoing, but also has a completion date | 2006-006130-17 | ACT-1 (younger patients) A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versu... | 2016-12-31 | bad-data |
Exempt, with results | 2008-007246-60 | Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma | 2017-06-30 | not-yet-due |
Listed as ongoing, but also has a completion date | 2010-023125-38 | Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk (aaIPI≥2) Diffuse Large B-Cell Lymphoma (NLG-LBC05) | 2020-05-25 | bad-data |
Ongoing | 2011-001557-85 | NLG-MCL5 (MARiT) Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 years A Nordic Lymphoma Group and British Lymphoma Group Phase-II Trial | not-yet-due | |
Reported results | 2013-005541-36 | A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma. | 2019-12-31 | due-trials |
Reported results | 2016-001058-16 | A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma. | 2021-09-30 | due-trials |
Ongoing | 2017-001060-38 | Venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma. | not-yet-due | |
Ongoing | 2018-001850-80 | Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma | not-yet-due |